Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MANBA | O00462 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | IDUA | P35475 | 1/20 | 0.56 |
| ▸ | GUSB | P08236 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14391479 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL16687559 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL14296856 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL12216738 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL25070350 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL19638526 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL23111379 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL23532013 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL1893475 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL17017514 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057795-A1 | LIQUID COMPOSITIONS, EYE DROPS, AND METHODS FOR TREATMENT OF EYE DISEASES USING Levodopa FORMULATIONS | MARTENS JOHN A (US) | 2025-02-20 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-10038177-B2 | Method for manufacturing storage battery electrode, storage battery electrode, storage battery, and electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| US-20170040590-A1 | METHOD FOR MANUFACTURING STORAGE BATTERY ELECTRODE, STORAGE BATTERY ELECTRODE, STORAGE BATTERY, AND ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LAB (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170040590-A1 | METHOD FOR MANUFACTURING STORAGE BATTERY ELECTRODE, STORAGE BATTERY ELECTRODE, STORAGE BATTERY, AND ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LAB (JP) | 2017-02-09 | — | — | US | disclosed |
| US-9478807-B2 | Method for manufacturing storage battery electrode, storage battery electrode, storage battery, and electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20160104892-A1 | METHOD FOR MANUFACTURING STORAGE BATTERY ELECTRODE, STORAGE BATTERY ELECTRODE, STORAGE BATTERY, AND ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LAB (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20150166348-A1 | GRAPHENE, GRAPHENE-INCLUDING LAYER, ELECTRODE, AND POWER STORAGE DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-8569441-B2 | Process for transforming the end groups of polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-10-29 | — | — | US | disclosed |
| US-8569441-B2 | Process for transforming the end groups of polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-10-29 | — | — | US | disclosed |
| US-8283436-B2 | Process for synthesizing thiol terminated polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-10-09 | — | — | US | disclosed |
| US-8283436-B2 | Process for synthesizing thiol terminated polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-10-09 | — | — | US | disclosed |
| US-20100137548-A1 | PROCESS FOR TRANSFORMING THE END GROUPS OF POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-06-03 | — | — | US | disclosed |
| WO-2009030733-A1 | METHOD FOR THE SYNTHESIS OF 4-ALKOXY-, 4-HYDROXY- AND 4-ARYLOXY-SUBSTITUTED TETRAHYDRO-FURO[3,4-B]FURAN-2(3H)-ONE COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2009-03-12 | — | — | WO | disclosed |
| US-20070232783-A1 | Process for synthesizing thiol terminated polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2007-10-04 | — | — | US | disclosed |
| US-20070232783-A1 | Process for synthesizing thiol terminated polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | LMNA 2758/4885HIF1A 799/4885MANBA 2967/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | LMNA 2374/4885HIF1A 3412/4885MANBA 246/4885 |
| US-20250057795-A1 | LIQUID COMPOSITIONS, EYE DROPS, AND METHODS FOR TREATMENT OF EYE DISEASES USING Levodopa FORMULATIONS | LOX, LOXL1, PDE6C | LMNA 407/4885HIF1A 4359/4885MANBA 2621/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | LMNA 2758/4885HIF1A 799/4885MANBA 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.